The clinically distinct aggressive subtype of breast cancer, triple negative breast cancer (TNBC) lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor 2 receptor (HER2) and is characterized by poor outcome [1–4]. This evidence concerns the gene ESR1 and breast carcinoma.